secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTENSITY THERAPEUTICS, INC. (INTS)
CIK:        0001567264
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001567264-25-000040
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intensity Therapeutics pauses Phase 3 sarcoma study enrollment; Q1 net loss $3.3M, cash $0.9M
--------------------------------------------------------------------------------

- Paused new site activations and enrollment in Phase 3 INVINCIBLE-3 sarcoma study due to funding constraints; 23 patients enrolled.
- April 2025 public offering raised $2.35M gross ($1.9M net) to prioritize Phase 2 INVINCIBLE-4 breast cancer trial.
- Q1 2025 net loss $3.3M (vs $4.6M Q1 2024); cash and equivalents $0.9M as of March 31, 2025.
- Eight Swiss sites activated in INVINCIBLE-4; EMA authorized study in France with Unicancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567264/000156726425000040/0001567264-25-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567264/000156726425000040/intensity-20250513.htm
  HTML page:      https://secwatch.observer/filing/0001567264-25-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer